| HOME | | | ABOUT ENLYTON | | | OUR TECHNOLOGY | | | PARTNERING OPPORTUNITIES | | | PRESS ROOM | | | CONTACT US |
| |||||||||||||||||||||
| “Developing non-radioisotope
labels for cancer detection in real time” |
|||||||||||||||||||||
 |
|||||||||||||||||||||
Technology - Detection
Dr. Edward W. Martin, Jr., pioneered the development of a hand-held probe for intraoperative use in the detection of hidden tumor tissue during cancer surgery. The original concept was that if cancer cells could be selectively labeled with a radioactive tracer it would be possible to find cancer that would not be apparent by inspection or palpation. This resulted in the development of a very sensitive probe system that enabled surgeons to locate cancer that was not otherwise apparent.
Enlyton’s ATA series antibody targets are derived from a family of monoclonal antibodies, antecedents for which have been approved for use in human clinical trials. ATA antibodies target a tumor-associated glycoprotein, TAG-72, a tumor surface antigen highly expressed in adenocarcinoma cancers – i.e., colorectal, pancreatic, ovarian, gastric, esophageal. Importantly, it was found that this byproduct of cancer enhances the metastatic spread of the disease. It is therefore vitally important to remove all affected tissues, particularly lymph nodes that express TAG-72.
Enlyton intends to retain the advantages of handheld probe concepts for use in the detection of cancer in real time. In parallel, Enlyton is developing fluorescence detection techniques that have shown promise for surgical use in the detection of occult tumor tissue.